Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1299 participants.
Also called NCT01387737
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,299 participants
- Sponsor
- Registry
-
NCT01387737
-
- Other papers using this trial's data
- Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01387737. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-04-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TA-7284-Low
- Intervention (Drug)
- TA-7284-High
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct01387737- Content hash
59a01b2bc701ada5e413cd8cf3e9e5aab6185199cd7a32a211fb0477140ec2b5